Carbiotix provides a Q3 update of LinkGut and CarbiAXOS activities
Oct 05, 2021, 08:45
Carbiotix (publ) ("Carbiotix" or “the Company”) today provides a Q3 update of LinkGut and CarbiAXOS activities. The Company has completed its first beta test of LinkGut in Q3 and will start the first full-scale rollout of the service in Q4 with a partner in North America. Carbiotix is also on track to complete renovations of its first CarbiAXOS production site in November and should have phase one of the first production line installed by the end of Q4.
Kristofer Cook, CEO for Carbiotix, comments
“I am very pleased to provide an update of our LinkGut and CarbiAXOS activities and am happy to report that we have made very good progress in both fields. Regarding LinkGut, our B2B white-label API service for consumer gut health testing, we have completed our first beta test with one of our North American partners in Q3. This follows the completion of our API service in Q1 and solution integration with this same partner in Q2. I am very happy to communicate that we will now begin to roll out our first full-scale LinkGut service in Q4. Simultaneously we will ramp up our marketing activities with our partner, which should lead to steady month-on-month growth of service revenues going forward.
We have also made good progress with our other signed partners and will begin beta tests in Q4 and Q1 2022 respectively. Moreover, the partner pipeline looks very promising and should allow us to continue with at least one new beta test each quarter going forward in 2022 and potentially well beyond. We see a clear increase in demand from the market and a shortening of the sales cycle, as well as the solution integration and beta testing periods for each new partner. LinkGut is today a key feature of our Smart Prebiotic value proposition. It is the most affordable, most reliable and flexible B2B consumer gut health testing service available in the global market. With each new partner added, we are confident that further economies of scale will be realised.
I am also happy to communicate that we are on track to complete renovations by the end of November of our first production site in Bjuv, Sweden, to produce our prebiotic soluble fiber ingredient CarbiAXOS. We should have phase one of the first production line installed by the end of the Q4. This is a major milestone for Carbiotix and marks the beginning of our scale-up activities. In parallel with this, several activities are underway. We are completing our first GRAS dossier based on our first site configuration, building out our partner network to support local production activities, and preparing for scale-up activities in Sweden and abroad. This first site in Sweden will play a key role in R&D activities over the long run and provide nutraceutical samples and products for sales in the coming two years as we build out the site. The upcoming start of CarbiAXOS sales activities will be an important milestone for the company.
Overall, I am extremely pleased with the progress we have made with both LinkGut and CarbiAXOS. Now we intend to start marketing the concept of Smart Prebiotics to the world and confidently establish ourselves in the rapidly growing market for prebiotics.”
This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 05 October 2021.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
For further information:
Kristofer Cook, CEO
Tel: +46 (0)708-796580
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.